Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.60 |
| ▸ | HTR2C | P28335 | 2/20 | 0.60 |
| ▸ | HTR2B | P41595 | 2/20 | 0.60 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.56 |
| ▸ | TUBB | P07437 | 3/20 | 0.56 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.56 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.56 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.56 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.56 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.56 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.56 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.56 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.56 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.56 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.56 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.56 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.56 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5871636 | 0.94 | TUBB4A (0.58) | HTR2AHTR2CHTR2BTUBB4ATUBB | |
| SCHEMBL5871797 | 0.92 | TUBB4A (0.57) | HTR2AHTR2CHTR2BTUBB4ATUBB | |
| SCHEMBL892587 | 0.88 | HTR2A (0.64) | HTR2AHTR2CHTR2BTUBB4ATUBB | |
| SCHEMBL7424861 | 0.87 | HTR2A (0.69) | HTR2AHTR2CHTR2BTUBB4ATUBB | |
| SCHEMBL4464142 | 0.83 | HTR2A (0.75) | HTR2AHTR2CHTR2BTUBB4ATUBB | |
| SCHEMBL5568951 | 0.82 | PTGS2 (0.63) | HTR2AHTR2CHTR2BTUBB4ATUBB | |
| SCHEMBL2007007 | 0.80 | TNKS2 (0.68) | HTR2AHTR2CHTR2BTUBB4ATUBB | |
| SCHEMBL16295765 | 0.80 | HTR2A (0.78) | HTR2AHTR2CHTR2BTUBB4ATUBB | |
| SCHEMBL9799524 | 0.80 | HTR2A (0.60) | HTR2AHTR2CHTR2BTUBB4ATUBB | |
| SCHEMBL6780613 | 0.80 | HTR2A (0.60) | HTR2AHTR2CHTR2BTUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0964851-A1 | C-TERMINAL KETONE HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES AND TNFA SECRETION | Abbott Laboratories (US) | 1999-12-22 | — | — | EP | claimed |
| WO-1998030541-A1 | C-TERMINAL KETONE HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES AND TNFA SECRETION | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | claimed |
| JP-9124487-A | — | — | None | — | — | JP | disclosed |
| EP-2621922-A1 | A PROCESS FOR THE SYNTHESIS OF THIO-TRIAZOLO-GROUP CONTAINING COMPOUNDS | BASF SE (DE) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041858-A1 | A PROCESS FOR THE SYNTHESIS OF THIO-TRIAZOLO-GROUP CONTAINING COMPOUNDS | BASF SE (DE) | 2012-04-05 | — | — | WO | disclosed |
| US-7071187-B2 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20040214853-A1 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1426374-A1 | NAPHTHYRIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-06-09 | — | — | EP | disclosed |
| EP-1069126-B1 | TRIAZOLOPURINE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVES, ADENOSINE A3 RECEPTOR COMPATIBILIZING AGENT, AND ASTHMATIC REMEDY | OTSUKA PHARMA CO LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| WO-2001091796-A2 | METHODS, COMPOUNDS AND COMPOSITIONS FOR TREATING GOUT | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| US-6288070-B1 | Triazolopurine derivatives, medicinal composition containing the derivatives, adenosine A3 receptor compatibilizing agent, and asthmatic remedy | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2001-09-11 | — | — | US | disclosed |
| EP-1069126-A1 | TRIAZOLOPURINE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVES, ADENOSINE A3 RECEPTOR COMPATIBILIZING AGENT, AND ASTHMATIC REMEDY | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2001-01-17 | — | — | EP | disclosed |
| JP-H09124487-A | RENAL DISEASE PREVENTING AND TREATING AGENT | KOWA CO | 1997-05-13 | — | — | JP | disclosed |
| US-4497815-A | 1-(N-Substituted carbamoyl)-5-fluorouracil derivatives and the carcinostatic agents containing same as active ingredients | Ozaki, Shoichiro (JP) | 1985-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214853-A1 | Naphthyridine derivatives | MT-ND1, OPRD1, NR0B1 | HTR2A 1845/4885HTR2C 1669/4885HTR2B 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.